AH004

AH004 is an investigational precision cancer therapy currently in preclinical development by Apricity Health. It is part of a pipeline of therapies designed to treat patients who do not respond to existing standard-of-care treatments. The development of AH004 utilizes Apricity Health's proprietary platform, which integrates real-world data and human insights to identify novel targets driving drug resistance. The program is intended to be biomarker-selected, using blood-based biomarkers for patient identification and precision clinical trial design. As of early 2024, the specific molecular target and modality of AH004 remain undisclosed as the asset progresses through preclinical proof-of-concept and toxicology studies.